Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

NCT07397338 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT07397338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07397338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 30, 2026
Completion date
May 31, 2029
Enrollment
370 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal cancer (crc), crc, metastatic solid tumors, non-small cell lung cancer (nsclc), nsclc